North Chicago, Illinois | April 12, 2026
AbbVie has announced late-breaking Phase 2 clinical trial results demonstrating strong efficacy of mirvetuximab soravtansine-gynx (ELAHEREĀ®) in combination with carboplatin for the treatment of platinum-sensitive ovarian cancer (PSOC). The data, presented at the Society of Gynecologic Oncology (SGO) Annual Meeting 2026, highlight a 62.7% objective response rate (ORR) and a favorable safety profile, reinforcing the potential of this first-in-class antibody-drug conjugate (ADC) to transform treatment paradigms in ovarian cancer. These findings are particularly significant given the ongoing need for more effective therapies in patients who experience disease recurrence after standard treatments.
Phase 2 Trial Demonstrates High Response Rates and Durability
The IMGN853-0420 Phase 2 trial evaluated mirvetuximab soravtansine-gynx in combination with carboplatin, followed by maintenance monotherapy, in patients with folate receptor alpha (FRĪ±)-expressing recurrent PSOC. The study enrolled 125 patients, many of whom had prior exposure to PARP inhibitors, a population known to have reduced responsiveness to subsequent therapies.
Results showed a confirmed ORR of 62.7% in patients with ā„50% FRĪ± expression, with consistent responses observed across the broader study population. Importantly, 81% of patients experienced no disease progression during the induction phase and continued into the maintenance phase, while the median duration of response reached 11.2 months, indicating sustained clinical benefit. Additionally, patients transitioning to single-agent maintenance therapy achieved an ORR of 68%, underscoring the durability of response with this treatment approach.
Innovative ADC Approach Enhances Precision Oncology
Advertisement
AbbVie continues to advance its oncology pipeline through targeted therapies such as antibody-drug conjugates, which combine the specificity of monoclonal antibodies with potent cytotoxic agents. Mirvetuximab soravtansine-gynx targets folate receptor alpha, a biomarker highly expressed in certain ovarian cancers, enabling selective delivery of chemotherapy directly to tumor cells.
This mechanism enhances efficacy while minimizing systemic toxicity, aligning with the broader shift toward precision medicine in oncology. The ADC incorporates a maytansinoid payload (DM4) designed to disrupt microtubule function and induce cancer cell death. The trial results further validate this targeted approach, particularly in patients with FRĪ±-positive tumors, where biomarker-driven therapy can significantly improve treatment outcomes.
Safety Profile and Clinical Implications for Ovarian Cancer Care
The safety findings from the trial were consistent with previous studies, with the majority of treatment-related adverse events (TRAEs) being manageable and low-grade. Common side effects included ocular events such as blurred vision and corneal changes, which were reversible in over 90% of patients. More serious adverse events, such as neutropenia, thrombocytopenia, and peripheral neuropathy, were observed but remained within acceptable limits for oncology therapies.
These results suggest that the combination regimen offers a balanced benefit-risk profile, making it a promising candidate for further clinical development. Although the combination therapy is not yet approved for PSOC, the data support continued investigation and potential expansion into earlier lines of treatment, potentially reshaping the standard of care for ovarian cancer patients.
The latest findings from AbbVie underscore the growing impact of antibody-drug conjugates and targeted oncology therapies in addressing unmet needs in cancer care. With strong efficacy signals, durable responses, and a manageable safety profile, mirvetuximab soravtansine-gynx represents a promising advancement in the treatment of platinum-sensitive ovarian cancer. As further studies continue, these results may pave the way for new therapeutic strategies and improved patient outcomes, reinforcing the role of precision medicine in modern oncology.
Source: AbbVie press release
